Medicure Past Earnings Performance
Past criteria checks 0/6
Medicure has been growing earnings at an average annual rate of 53.7%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
53.7%
Earnings growth rate
49.5%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 4.2% |
| Return on equity | -13.5% |
| Net Margin | -12.6% |
| Next Earnings Update | 26 Nov 2024 |
Recent past performance updates
Recent updates
Medicure Inc.'s (CVE:MPH) Price Is Right But Growth Is Lacking
Jul 31
Estimating The Fair Value Of Medicure Inc. (CVE:MPH)
May 14Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease
Aug 28Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem
Nov 30Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely
Jun 15Revenue & Expenses Breakdown
How Medicure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 21 | -3 | 13 | 3 |
| 31 Mar 24 | 22 | -1 | 13 | 3 |
| 31 Dec 23 | 22 | -1 | 12 | 2 |
| 30 Sep 23 | 23 | 1 | 12 | 2 |
| 30 Jun 23 | 23 | 2 | 12 | 2 |
| 31 Mar 23 | 23 | 1 | 12 | 3 |
| 31 Dec 22 | 23 | 1 | 12 | 3 |
| 30 Sep 22 | 24 | 3 | 12 | 2 |
| 30 Jun 22 | 23 | 1 | 13 | 2 |
| 31 Mar 22 | 23 | 1 | 13 | 2 |
| 31 Dec 21 | 22 | -1 | 13 | 2 |
| 30 Sep 21 | 17 | -7 | 13 | 3 |
| 30 Jun 21 | 16 | -7 | 12 | 4 |
| 31 Mar 21 | 14 | -6 | 11 | 3 |
| 31 Dec 20 | 12 | -7 | 10 | 3 |
| 30 Sep 20 | 13 | -18 | 10 | 3 |
| 30 Jun 20 | 15 | -18 | 12 | 3 |
| 31 Mar 20 | 18 | -18 | 15 | 4 |
| 31 Dec 19 | 20 | -20 | 17 | 4 |
| 30 Sep 19 | 25 | -3 | 19 | 6 |
| 30 Jun 19 | 26 | -3 | 20 | 7 |
| 31 Mar 19 | 28 | 0 | 21 | 7 |
| 31 Dec 18 | 29 | 4 | 20 | 7 |
| 30 Sep 18 | 26 | 10 | 17 | 5 |
| 30 Jun 18 | 26 | 12 | 16 | 4 |
| 31 Mar 18 | 26 | 12 | 15 | 5 |
| 31 Dec 17 | 27 | 11 | 15 | 5 |
| 30 Sep 17 | 29 | 5 | 14 | 4 |
| 30 Jun 17 | 31 | 5 | 14 | 4 |
| 31 Mar 17 | 30 | 4 | 15 | 4 |
| 31 Dec 16 | 29 | 4 | 15 | 4 |
| 30 Sep 16 | 32 | 5 | 15 | 4 |
| 30 Jun 16 | 29 | 2 | 14 | 6 |
| 31 Mar 16 | 25 | 2 | 11 | 5 |
| 31 Dec 15 | 22 | 2 | 10 | 5 |
| 31 Dec 14 | 9 | 2 | 6 | 1 |
| 31 Aug 14 | 6 | 0 | 4 | 1 |
| 31 May 14 | 5 | -2 | 4 | 1 |
| 28 Feb 14 | 4 | -2 | 3 | 1 |
| 30 Nov 13 | 3 | -3 | 3 | 2 |
Quality Earnings: MPH is currently unprofitable.
Growing Profit Margin: MPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MPH is unprofitable, but has reduced losses over the past 5 years at a rate of 53.7% per year.
Accelerating Growth: Unable to compare MPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MPH has a negative Return on Equity (-13.46%), as it is currently unprofitable.